Biocept
Biocept Licenses CNSide Liquid Biopsy Assay to Plus Therapeutics
Under the agreement, Plus is using the cerebrospinal fluid cell-based assay in its ongoing clinical trial of the radiotherapeutic rhenium 186 obisbemeda.
In Brief This Week: Biocept, Quest, Agilent, MDxHealth, OpGen, More
News items for the week of May 15, 2023.
Plus Therapeutics, Biocept Ink Lab Services Agreement for ReSPECT-LM Trial
Biocept will test patients with its CNSide cerebrospinal fluid cell capture assay to evaluate responses to Plus' radiotherapy drug candidate.
Biocept to Refocus CNSide Assay Plans After FDA Feedback Suggests Targeting Narrower Indications
Premium
The company failed in its first bid for breakthrough device designation but has now split out new specific indications for which it is building more persuasive utility data.
Quest Diagnostics to Offer Biocept's Target Selector NGS Lung Cancer Test
The liquid biopsy test is intended for identifying genetic mutations to guide therapy in patients with advanced non-small cell lung cancer.
Mar 31, 2021
May 21, 2019